EICHORPublic-registry trials using Ublituximab that Eichor's radar has found — 4 trials. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | TG Therapeutics, Inc. | Diffuse Large B-Cell Lymphoma | PHASE2 / PHASE3 | 168 |
| An Extension of the TG1101-RMS201 Trial | TG Therapeutics, Inc. | Relapsing Remitting Multiple Sclerosis | PHASE2 | 8 |
| Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia | TG Therapeutics, Inc. | Schizophrenia | PHASE2 | 0 |
| A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) | TG Therapeutics, Inc. | Myasthenia Gravis | PHASE2 | 2 |
| First FDA approval | BRIUMVI — December 2022 (application BLA761238, currently held by TG THERAPEUTICS, INC) |
| Also known as | BRIUMVI |
| Approved applications | 1 |
| Forms & routes | Injectable · Intravenous |
Source: FDA Drugs@FDA, a public record. The application holder shown is the current holder, which may differ from the original developer.
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Diffuse Large B-Cell Lymphoma drugs
← Eichor home · All tracked trials · Diffuse Large B-Cell Lymphoma studies · Weekly briefs
